NCT02494206View on ClinicalTrials.gov

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Breast CancerUpper Extremity Lymphedema
Interventions
DRUG

QBX258

Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER